US Stock Market Move | BlossomHill Therapeutics (BLSM.US) debuts on the US stock market, with the stock price slightly declining after opening.
As of the time of this report, the stock has dropped over 1%, trading at $15.8.
On Friday, BlossomHill Therapeutics (BLSM.US) made its debut on the U.S. stock market. As of the time of writing, the stock had dropped over 1%, trading at $15.80. BlossomHill Therapeutics is headquartered in San Diego, California, and was established in 2020. The company focuses on developing small molecule cancer drugs by identifying structural weaknesses in existing therapies and designing new compounds to overcome these weaknesses. The companys core candidate drug, BH-30643, which targets EGFR-mutant non-small cell lung cancer (NSCLC), is currently undergoing global Phase 1/2 clinical trials. The company plans to hold a Phase 1 clinical end-of-trial meeting with the U.S. Food and Drug Administration (FDA) in the fourth quarter of 2026 to discuss the recommended Phase 2 clinical dosing regimen and potential accelerated approval pathways for certain patients.
Related Articles
US Stock Market Move | Ticketplus Ltd (TP.US) debuted on the U.S. stock market, dropping over 15% after opening.
US Stock Market Move | Latigo Biotherapeutics (LTGO.US) debuts on the U.S. stock market, with its stock price rising over 14% after opening.
In July, the U.S. non-farm payroll unexpectedly turned negative, dealing a heavy blow to the dollar. The market has lowered its expectations for a rate hike in September, and the Federal Reserve may continue to hold its position.
US Stock Market Move | Ticketplus Ltd (TP.US) debuted on the U.S. stock market, dropping over 15% after opening.
US Stock Market Move | Latigo Biotherapeutics (LTGO.US) debuts on the U.S. stock market, with its stock price rising over 14% after opening.
In July, the U.S. non-farm payroll unexpectedly turned negative, dealing a heavy blow to the dollar. The market has lowered its expectations for a rate hike in September, and the Federal Reserve may continue to hold its position.
RECOMMEND
